Cargando…

Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis

BACKGROUND: Many clinical trials have shown the efficacy of aromatase inhibitors (AIs) in the management of breast cancer (BC). There is growing evidence that CYP19A1 single-nucleotide polymorphisms (SNPs) are associated with clinical response (CR) and adverse effects (AEs) among BC patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Artigalás, Osvaldo, Vanni, Tazio, Hutz, Mara Helena, Ashton-Prolla, Patricia, Schwartz, Ida Vanessa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4475294/ https://www.ncbi.nlm.nih.gov/pubmed/26067721 http://dx.doi.org/10.1186/s12916-015-0373-9

Ejemplares similares

BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
por: Alemar, Bárbara, et al.
Publicado: (2017)

Correction: BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
por: Alemar, Bárbara, et al.
Publicado: (2018)

Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors
por: Mao, Jun J, et al.
Publicado: (2011)

Analysis of the rs10046 Polymorphism of Aromatase (CYP19) in Premenopausal Onset of Human Breast Cancer
por: Zins, Karin, et al.
Publicado: (2014)

Pyridine based dual binding site aromatase (CYP19A1) inhibitors
por: Eissa, Ahmed G., et al.
Publicado: (2023)

The Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy?
por: Glubb, Dylan M., et al.
Publicado: (2017)

Polymorphisms in the CYP2E1 and GSTM1 Genes as Possible Protection Factors for Leprosy Patients
por: Pinto, Pablo, et al.
Publicado: (2012)

CYP1A2 – a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients
por: Simonsson, Maria, et al.
Publicado: (2016)

Genetic variants of CYP19 (aromatase) and breast cancer risk
por: Nedelcheva Kristensen, V, et al.
Publicado: (2000)

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer
por: Colomer, R, et al.
Publicado: (2005)

A Polymorphism at the 3′-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
por: Liu, Lei, et al.
Publicado: (2013)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor
por: Schwartz, Melissa, et al.
Publicado: (2015)

Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2017)

Simple tandem repeat (TTTA)(n )polymorphism in CYP19 (aromatase) gene and breast cancer risk in Nigerian women
por: Okobia, Michael N, et al.
Publicado: (2006)

Global Pharmacogenomics: Distribution of CYP3A5 Polymorphisms and Phenotypes in the Brazilian Population
por: Suarez-Kurtz, Guilherme, et al.
Publicado: (2014)

A patient presenting a 22q13 deletion associated with an apparently balanced translocation t(16;22): An illustrative case in the investigation of patients with low ARSA activity
por: Artigalás, Osvaldo, et al.
Publicado: (2012)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Aromatase inhibitors in male sex
por: Singh, Santosh Kumar
Publicado: (2013)

Aromatase inhibitors in the treatment of endometriosis
por: Słopień, Radosław, et al.
Publicado: (2016)

Molecular Docking of Aromatase Inhibitors
por: Suvannang, Naravut, et al.
Publicado: (2011)

Aromatase Inhibitors in Erectile Dysfunction
por: Singh, Santosh
Publicado: (2021)

Delineating the role of single-nucleotide polymorphism of CYP19 gene on aromatase activity in South Indian women with polycystic ovary syndrome
por: Hegde, Pravesh, et al.
Publicado: (2023)

Association Study of Aromatase Gene (CYP19A1) in Essential Hypertension
por: Shimodaira, Masanori, et al.
Publicado: (2008)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

Associations between Aromatase CYP19 rs10046 Polymorphism and Breast Cancer Risk: From a Case-Control to a Meta-Analysis of 20,098 Subjects
por: Pineda, Begoña, et al.
Publicado: (2013)

Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk
por: Siegelmann-Danieli, N, et al.
Publicado: (1999)

Cyp19a1 (Aromatase) Expression in the Xenopus Brain at Different Developmental Stages
por: Coumailleau, P, et al.
Publicado: (2014)

Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer
por: Daldorff, Stine, et al.
Publicado: (2017)

Aromatase Deficiency due to a Novel Mutation in CYP19A1 Gene
por: Unal, Edip, et al.
Publicado: (2018)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

The effects of aromatase inhibitors on lipids and thrombosis
por: Bundred, N J
Publicado: (2005)

Safety of aromatase inhibitors in the adjuvant setting
por: Perez, Edith A.
Publicado: (2007)

Aromatase inhibitors--where are we now?
por: Miller, W. R.
Publicado: (1996)

Aromatase inhibitors in stimulated IVF cycles
por: Papanikolaou, Evangelos G, et al.
Publicado: (2011)

Aromatase inhibitors in post-menopausal endometriosis
por: Polyzos, Nikolaos P, et al.
Publicado: (2011)

Management of aromatase inhibitor–induced arthralgia
por: Younus, J., et al.
Publicado: (2010)

Understanding the mechanisms of aromatase inhibitor resistance
por: Miller, William R, et al.
Publicado: (2012)

Use of aromatase inhibitors in practice of gynecology
por: Usluogullari, Betul, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_37cav15l6emjhhotogn60ip66j